- Home
- CYH vs EYPT Comparison
CYH vs EYPT Comparison
Compare CYH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | EYPT |
|---|---|---|
| Founded | 1985 | 1987 |
| Country | United States | United States |
| Employees | N/A | 214 |
| Industry | Hospital/Nursing Management | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 1.1B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CYH | EYPT |
|---|---|---|
| Price | $2.94 | $13.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $3.57 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 04-22-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | N/A |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $12,485,000,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | $1,031.72 |
| P/E Ratio | $0.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $3.91 |
| 52 Week High | $4.43 | $19.11 |
Technical Indicators
Market Signals| Indicator | CYH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 39.10 |
| Support Level | $2.41 | $12.47 |
| Resistance Level | $3.25 | $13.32 |
| Average True Range (ATR) | 0.15 | 0.84 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 16.00 | 22.70 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.